<DOC>
	<DOCNO>NCT01764243</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy assess Alzheimers Disease Assessment Scale-cognitive subscale 13-item ( ADAS-cog-13 ) two dose MT-4666 placebo administer daily 24 week subject mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Safety Efficacy MT-4666</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Probable Alzheimer 's disease consistent National Institute Neurological Communicative Disorders Stroke ( NINCDS ) Alzheimer 's Disease Related Disorders Association ( ADRDA ) criterion MMSE score 10 24 inclusive screen Day 1 , CDRSB score ≥ 2 screen Modified Hachinski Ischemic Score ( mHIS ) ≤ 4 screening Caregiver available ; caregiver see subject least four day ( least 12 hour ) week Subject living home ; live senior residential setting , institutional setting , subject caregiver indicate available Inability perform cognitive test ( ADAScog13 MMSE ) screen Day 1 Diagnosis disease may cause dementia MRI CT scan within 6 month screen , finding inconsistent diagnosis Probable AD Diagnosis major depressive disorder define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) within last five year History current diagnosis psychosis History myocardial infarction unstable angina within six month screen History cerebrovascular disorder within 18 month screen</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Nicotinic Acetylcholine Receptor Agonist</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>Dementia</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>